2026 年 02 月 05 日 行业日报 看好/维持 医药 医药 | 化学制药 | 无评级 | | --- | --- | | 中药生产 | 无评级 | | 生物医药Ⅱ | 中性 | | 其 他 医 药 医 | 中性 | | 疗 | | 太平洋医药日报（20260205）：艾伯维 Rinvoq 递交欧美上市申请 (10%) 0% 10% 20% 30% 40% 25/2/5 25/4/19 25/7/1 25/9/12 25/11/24 26/2/5 ◼ 子行业评级 相关研究报告 <<太平洋医药日报（20260203）：诺华 司库奇尤单抗新适应症在华获批>>- -2026-02-05 <<太平洋医药日报（20260202）： Lirafugratinib 向 FDA 递交 NDA>>-- 2026-02-04 <<太平洋医药日报（20260130）： Summit 在研双抗 Ivonescimab 上市 申请获 FDA 受理>>--2026-02-01 证券分析师：周豫 电话： E-MAIL：zhouyua@tpyzq.com 分析师登记编号：S1190523060002 ◼ 走势比较 证券分析师：张崴 电 ...

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a decline of 2.42% on February 2, 2025, underperforming the CSI 300 index by 0.29 percentage points, ranking 16th among 31 sub-industries [4]. - Key performers in the sector included hospitals (-0.99%), pharmaceutical distribution (-1.63%), and blood products (-1.65%), while other biopharmaceuticals (-3.69%) and offline pharmacies (-3.09%) lagged behind [4]. - Elevar has submitted a New Drug Application (NDA) to the FDA for Lirafugratinib, a selective oral FGFR2 inhibitor, showing a 46.5% objective response rate (ORR) in clinical trials for cholangiocarcinoma patients [5]. - The disease control rate for Lirafugratinib reached 96.5%, with a median progression-free survival (PFS) of 11.3 months and a median overall survival (OS) of 22.8 months [5]. - Jichuan Pharmaceutical has signed an exclusive commercialization agreement for a nasal spray in Greater China, with a payment of up to 100 million RMB [5]. - Heng Rui Pharmaceutical received FDA acceptance for its BLA submission for a combination therapy for liver cancer [6]. - Shanghai Yizhong reported a projected revenue of 317 million RMB for 2025, reflecting an 82.72% year-on-year growth [6]. Sub-industry Ratings - Chemical pharmaceuticals: No rating - Traditional Chinese medicine: No rating - Biopharmaceuticals II: Neutral - Other pharmaceuticals: Neutral [3].

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a gain of 1.26% on January 23, 2025, outperforming the CSI 300 index by 1.71 percentage points, ranking 10th among 31 sub-industries in the Shenwan classification. Notable performers included offline pharmacies (+6.79%), pharmaceutical distribution (+2.66%), and vaccines (+2.26%), while blood products (+0.58%), medical R&D outsourcing (+0.68%), and in vitro diagnostics (+1.37%) lagged behind [4]. - Takeda's new drug Oveporexton has been proposed for priority review by the National Medical Products Administration (NMPA) in China, aimed at treating narcolepsy type 1 in patients aged 16 and above. The drug has shown positive results in two pivotal Phase 3 studies [5]. Sub-industry Summary - Chemical Pharmaceuticals: No rating [3] - Traditional Chinese Medicine: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other Pharmaceuticals: Neutral [3]

Group 1 - The latest stock price of Xinguang Pharmaceutical is 20.05 yuan, an increase of 0.25 yuan from the previous trading day [1] - The stock opened at 18.86 yuan, reached a high of 20.28 yuan, and a low of 18.15 yuan, with an overall fluctuation of 10.76% throughout the day [1] - The trading volume was 260,458 hands, with a total transaction amount of 491 million yuan [1] Group 2 - Xinguang Pharmaceutical operates in the pharmaceutical manufacturing industry, specifically in the traditional Chinese medicine production sector [1] - The company is primarily engaged in the research, development, production, and sales of traditional Chinese medicine, chemical drug formulations, and raw materials [1] - Its product range covers multiple therapeutic areas, including cardiovascular, digestive, and respiratory systems [1] Group 3 - On August 4, the stock experienced a rapid rebound during the morning trading session, with a rise of over 2% within 5 minutes [1] - As of 9:37 AM, the stock price was reported at 18.95 yuan, with a transaction amount reaching 105 million yuan [1] - In terms of capital flow, there was a net outflow of 4.5732 million yuan from the main funds on that day, accounting for 0.2% of the circulating market value [1] - Over the past five trading days, the cumulative net inflow of main funds was 22.5547 million yuan, representing 0.99% of the circulating market value [1]

Group 1 - The core viewpoint of the articles highlights the surge in mergers and acquisitions (M&A) activity in Shenzhen following the release of the "Six M&A Guidelines" by the China Securities Regulatory Commission (CSRC), which aims to enhance the role of capital markets in corporate restructuring and support the integration of quality assets [1][2][3] - Since the introduction of the "Six M&A Guidelines," Shenzhen listed companies have disclosed 263 new M&A transactions, with 196 transactions revealing a total deal value exceeding 57 billion yuan [1][3] - The policies encourage companies to pursue strategic mergers and acquisitions, particularly in emerging industries, to enhance their business layouts and drive high-quality development [2][3] Group 2 - Specific examples of recent M&A activities include China Resources Sanjiu acquiring 28% of Tianshili's shares to strengthen its position in the traditional Chinese medicine sector, and Luxshare Precision acquiring part of Wentai Technology to enhance its resources in the Android ecosystem [1][3] - The articles emphasize the role of state-owned enterprises in accelerating business integration, with China General Nuclear Power Corporation acquiring 100% of the shares of Taishan Nuclear Power, which will help increase its nuclear power generation capacity and market share [3] - Shenzhen's unique ecosystem, characterized by a high concentration of high-tech enterprises and a robust private equity market, provides fertile ground for M&A activities, with over 20,000 national high-tech enterprises and more than 1.5 trillion yuan in private equity fund management [4][5] Group 3 - The establishment of the Shenzhen M&A Fund Alliance, which includes 240 participating institutions, aims to enhance collaboration among various financial entities to support M&A activities [5] - The Shenzhen Securities Regulatory Bureau is actively building a resource database for M&A projects, which currently includes over 500 potential acquisition targets, primarily focusing on specialized and innovative technology companies [5][6] - Future initiatives will include ongoing policy promotion, resource database enhancement, and targeted matchmaking events to facilitate M&A transactions [6]

Investment Rating - The industry investment rating is positive, with expectations of overall returns exceeding the CSI 300 index by more than 5% in the next six months [11]. Core Insights - The introduction of the "Measures to Support the High-Quality Development of Innovative Drugs" marks a significant opportunity for the innovative drug sector, addressing key challenges in research, payment, and clinical application [4][8]. - The report emphasizes a comprehensive support system for innovative drug development, including the use of national health insurance data to guide research directions and enhance innovation efficiency [5]. - The measures aim to optimize the inclusion of innovative drugs in the basic medical insurance catalog and commercial health insurance, ensuring that they meet clinical value and market conditions [6][9]. - The report highlights the potential for innovative drugs to expand their market reach, both domestically and internationally, under the Belt and Road Initiative, enhancing accessibility for patients [9]. Summary by Sections Industry Ratings - Sub-industry ratings for chemical pharmaceuticals, traditional Chinese medicine, and biopharmaceuticals are currently not rated [3]. Recommended Companies and Ratings - Companies such as Kelun-Botai, Kangfang Biotech, Lepu Biotech, Maiwei Biotech, and Ailis are expected to experience a new round of high-quality development opportunities, maintaining a "buy" rating [9].

Core Viewpoint - The financial performance of Buchang Pharma has significantly deteriorated in 2024, with a revenue drop of 17% and a net loss of 5.5 billion yuan, marking a 274% decline in net profit compared to the previous year [2][3][4]. Financial Performance Summary - In 2024, the company's operating revenue was 11 billion yuan, down from 13.25 billion yuan in 2023, reflecting a decrease of 16.91% [3]. - The net profit attributable to shareholders was a loss of 553.8 million yuan, compared to a profit of 319 million yuan in 2023, indicating a decline of 273.62% [3][4]. - The company reported a significant impairment of goodwill amounting to 853 million yuan, primarily related to its subsidiaries Tonghua Guhong and Jilin Tiancai [5][20]. Business Operations and Challenges - The decline in revenue and profit is attributed to the removal of several products from the medical insurance catalog and increased scrutiny on certain products, leading to reduced sales [4][13]. - The company's total revenue has decreased from 160 billion yuan in 2020 to 110 billion yuan in 2024, a drop of over 30% [16]. - Sales of key products have plummeted, with some experiencing a sales decline of 50% to 85% from 2022 to 2023 [18]. Acquisition and Goodwill Issues - Buchang Pharma's acquisitions of Jilin Tiancai and Tonghua Guhong from 2012 to 2015 resulted in a total goodwill of approximately 49.97 billion yuan, which constituted 33% of the company's total assets at that time [8][9]. - The company has faced continuous goodwill impairment, totaling 45.3 billion yuan from 2021 to 2024, which is 88% of the initial goodwill [24]. Sales and Marketing Expenses - The company's sales expense ratio has consistently exceeded the industry average, with a sales expense rate of 39% in 2024, 11 percentage points higher than the industry average [27][28]. - A significant portion of sales expenses (93%) is allocated to market and academic promotion fees, raising concerns about the efficiency of spending [29][30]. Research and Development (R&D) Expenditure - Despite claims of transitioning to a product-driven and technology-oriented company, R&D expenditure has remained low, with a rate of only 2-3% over the past five years [35]. - The company has increasingly capitalized R&D expenses, with the capitalized portion rising from 26% in 2020 to 52% in 2024, suggesting potential manipulation of profit figures [37][38].

Core Viewpoint - The financial performance of Buchang Pharma has significantly deteriorated in 2024, with a revenue drop of 17% and a net loss of 5.5 billion yuan, marking a 274% decline in net profit compared to the previous year [2][3][4]. Financial Performance Summary - In 2024, the company's operating revenue was 11 billion yuan, down from 13.25 billion yuan in 2023, reflecting a decrease of 16.91% [3]. - The net profit attributable to shareholders was a loss of 553.8 million yuan, compared to a profit of 319 million yuan in 2023, indicating a decline of 273.62% [3][4]. - The company also reported a significant impairment of goodwill amounting to 853 million yuan, primarily related to its subsidiaries [5][20]. Business Operations and Challenges - The decline in revenue and profit is attributed to the removal of several products from the medical insurance catalog and increased scrutiny on certain products, leading to reduced sales [4][13]. - The company has faced continuous challenges since 2020, with total revenue decreasing from 160 billion yuan in 2020 to 110 billion yuan in 2024, a drop of over 30% [16]. Goodwill Impairment and Acquisitions - Buchang Pharma's acquisitions of Jilin Tiancai and Tonghua Guhong from 2012 to 2015 resulted in a total goodwill of approximately 50 billion yuan, which constituted 33% of the company's total assets at that time [8][9]. - The company has been forced to recognize substantial goodwill impairments, totaling 45.3 billion yuan from 2021 to 2024, which is 88% of the initial goodwill [24]. Sales and Marketing Expenses - The company's sales expense ratio has consistently exceeded the industry average, with a sales expense rate of 39% in 2024, significantly higher than the industry average of 28% [27][28]. - A large portion of the sales expenses (93%) is allocated to market and academic promotion fees, raising concerns about the efficiency of spending [29][30]. Research and Development - Despite claims of transitioning to a product-driven and technology-driven company, Buchang Pharma's R&D expenditure has remained low, with a research expense rate of only 2-3% over the past five years [35]. - The company has increasingly capitalized its R&D expenses, with the capitalized portion rising from 26% in 2020 to 52% in 2024, which may obscure the true profitability [37][38].

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding 5% above the CSI 300 index in the next six months [13]. Core Views - The pharmaceutical sector experienced a decline of 0.84% on March 24, 2025, underperforming the CSI 300 index by 1.35 percentage points, ranking 21st among 31 sub-industries [5]. - Notable performances within sub-industries include vaccines (+0.17%) and medical research outsourcing (-0.16%), while hospitals (-2.17%) and medical devices (-1.35%) lagged [5]. - Alnylam's RNAi therapy Vutrisiran has received FDA approval for treating wild-type or hereditary ATTR-CM in adults, aimed at reducing cardiovascular mortality and hospitalizations [6]. Summary by Sections Market Performance - On March 24, 2025, the pharmaceutical sector's performance was -0.84%, underperforming the CSI 300 index by 1.35% [5]. - The top three gainers were Tianyu Co. (+9.95%), Zhongyuan Qihe (+8.82%), and Shanwaishan (+6.60%), while the largest decliners were Aipeng Medical (-10.22%), Innovation Medical (-9.97%), and Sanbo Brain Science (-8.99%) [5]. Industry News - Alnylam announced FDA approval for Vutrisiran, a subcutaneous RNAi therapy targeting specific mRNA to block the production of transthyretin protein, enhancing efficacy and metabolic stability [6]. - Garden Biologics reported a 13.58% year-on-year increase in revenue to 1.243 billion yuan for 2024, with a net profit growth of 60.76% to 309 million yuan [7]. - Shouxiangu reported a 10.87% decline in revenue to 699 million yuan for 2024, with a net profit decrease of 27.87% to 184 million yuan [7].

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding 5% above the CSI 300 index within the next six months [10]. Core Insights - The pharmaceutical sector showed a performance increase of +0.86% on March 18, 2025, outperforming the CSI 300 index by 0.59 percentage points, ranking fourth among 31 sub-industries in the Shenwan classification [4]. - Avidity's investigational therapy, delpacibart zotadirsen (del-zota), demonstrated unprecedented efficacy in protein expression during its Phase 1/2 clinical trial, with significant increases in skeletal muscle delivery and protein generation [5]. - The report highlights the performance of various sub-sectors, with medical research outsourcing (+5.56%) and hospitals (+1.34%) leading, while medical devices (+0.09%) and vaccine sectors (+0.27%) lagged behind [4]. Sub-industry Ratings - Chemical pharmaceuticals: No rating - Traditional Chinese medicine production: No rating - Biopharmaceutical II: Neutral - Other pharmaceutical sectors: Neutral [3]. Recommended Companies and Ratings - The report does not specify individual company ratings but emphasizes the overall positive outlook for the pharmaceutical industry [3].